SEC Tracker
Get the app

AVROBIO TECX

AVROBIO FY 2023: net income $12.2M; diluted EPS $0.51

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers AVROBIO reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income$12.2MAgainst −$105.9M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS$0.51Against −$4.57 in FY 2022. Split-adjusted, as the tables show it; the filing reported $0.2710-K income statement, on EDGAR
  3. Cash and cash equivalents$98.0M+6% from $92.6M in FY 202210-K balance sheet, on EDGAR
  4. Cash from operations−$63.2MAgainst −$97.2M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when AVROBIO files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  2. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025
  5. Annexon ANNX public float $244M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.